{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.12","upperLimit":"0.32","value":"0.170"},{"groupId":"OG001","lowerLimit":"0.12","upperLimit":"0.22","value":"0.170"},{"groupId":"OG002","lowerLimit":"0.08","upperLimit":"0.50","value":"0.370"},{"groupId":"OG003","lowerLimit":"0.17","upperLimit":"0.32","value":"0.300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received eribulin mesylate 1.1 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.","id":"OG000","title":"Part A1: Eribulin Mesylate 1.1 mg/m2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG001","title":"Part A1: Eribulin Mesylate 1.4 mg/m2"},{"description":"Participants received eribulin mesylate 1.8 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG002","title":"Part A1: Eribulin Mesylate 1.8 mg/m2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.","id":"OG003","title":"Part A1: Eribulin Mesylate PK Expansion"}],"paramType":"MEDIAN","populationDescription":"The PAS included all participants who had sufficient PK data to derive at least one PK parameter.","reportingStatus":"POSTED","timeFrame":"Day 1 predose and at 10, 30 minutes, 1, 2, 4, 6, 24, 48, 72, 96 or 120 hours post-dose","title":"Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Eribulin Mesylate","type":"PRIMARY","unitOfMeasure":"hours"}